SR9009 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-23. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
== Side effects == Long term use may result in blepharospasms, especially in women. Doses of 4 mg or more may cause anterograde amnesia. In rare cases, erythema annulare centrifugum skin lesions have resulted.
=== Acid-base reactions === Carboxylic acids react with bases to form carboxylate salts, in which the hydrogen of the hydroxyl (–OH) group is replaced with a metal cation. For example, acetic acid found in vinegar reacts with sodium bicarbonate (baking soda) to form sodium acetate, carbon dioxide, and water:
== Continuum Assumption == The continuum assumption is an idealization of continuum mechanics under which fluids can be treated as continuous, even though, on a microscopic scale, they are composed of molecules. Under the continuum assumption, macroscopic (observed/measurable) properties such as density, pressure, temperature, and bulk velocity are taken to be well-defined at "infinitesimal" volume elements—small in comparison to the characteristic length scale of the system, but large in comparison to molecular length scale. Fluid properties can vary continuously from one volume element to another and are average values of the molecular properties. The continuum hypothesis can lead to inaccurate results in applications like supersonic speed flows, or molecular flows on nano scale. Those problems for which the continuum hypothesis fails can be solved using statistical mechanics or rarefied gas dynamics. To determine whether or not the continuum hypothesis applies, the Knudsen number, defined as the ratio of the molecular mean free path to the characteristic length scale, is evaluated. Problems with Knudsen numbers below 0.1 can be evaluated using the continuum hypothesis, but molecular approach (statistical mechanics) can be applied to find the fluid motion for larger Knudsen numbers.
=== Recognition === Cooper was awarded the NASA Distinguished Service Medal by President John F. Kennedy at the White House on May 21, 1963. He also addressed a joint session of the U.S. Congress on the same day. Accomplishments of the Mercury 9 mission and Astronaut Gordon Cooper were celebrated in New York City with a ticker tape parade down the Canyon of Heroes (Broadway) on May 22, 1963, with millions turning out.
Sources: en.wikipedia.org
=== New Zealand in 1998 === In 1998 he walked from Cape Reinga in the North Island, to Bluff, at the southern tip of New Zealand; a distance of 1,500 miles (2,400 km). On the journey he walked through the active volcano at White Island, experienced earthquakes up to 4.9 on the Richter Scale, clambered over glaciers, swam with seals and reported on conservation biology projects involving endangered species. Information from the journey was posted on the Internet for schoolchildren in the U.S. via the Scholastic Corporation Scholastic Network. In December 2010 Skinner completed a book about the journey and conservation biology, New Zealand – 1500 miles on foot through – The Land of the Long White Cloud on an Internet website. In 1999 he obtained a PGCE (Postgraduate Certificate in Education) from Canterbury Christ Church University in Canterbury, England. In 2000 he worked as a secondary school science teacher at St. Edmund's School in Dover, teaching 11 to 16-year-olds. In 2001 he worked as a volunteer at a wildlife park, working on enrichment activities for animals. From 2001 until 2003 he worked part-time at a post office. During this time, he also taught science to primary school children, in a 'Link-Scientist' scheme run by the pharmaceutical company Pfizer, and took care of his son. In 2003 his mother died from pancreatic cancer, at the age of 59. This prompted him to write the story of the 6,000 miles (9,700 km) journey across Britain and America.
== Liquid-phase reactions == Chemiluminescence was first observed with lophine (triphenylimidazole). When in basic solution, this compound converts to imidazolate, which reacts with oxygen to eventually give a dioxetane. Fragmentation of dioxetane gives the excited state of an anionic diamide.
=== Structural Variants === The most widely used sortase in biological and medical applications is the SrtA enzyme found in staphylococcus aureus bacteria, which recognizes an LPXTG binding motif. Different sortase enzymes found in staphylococcus and other bacteria have other recognition sequences. SrtB for example recognizes a NPQTN binding sequence. These other sortase variants have different properties including different binding motifs and reaction efficiencies. To use the sortase enzyme in broader applications new variations of the enzyme have been developed to exhibit desired properties. SrtA variants that exhibit similar kinetics and catalytic efficiency to the wild type have been engineered using directed evolution. This process induces mutations in the natural enzyme and selects for mutations that result in the desired properties. SrtA variants have been developed with different binding motifs (LPXSG and LAXTG). Another sortase variant, eSrtA, was specifically developed to have improved kinetics, while still other variants were developed to operate in the absence of calcium.
Sources: en.wikipedia.org
As of 2008, the United States is the leader in medical research, including pharmaceutical development. U.S. drug prices are among the highest in the world, and drug innovation is correspondingly high. In 2000, U.S.-based firms developed 29 of the 75 top-selling drugs; firms from the second-largest market, Japan, developed eight, and the United Kingdom contributed 10. France, which imposes price controls, developed three. Throughout the 1990s, outcomes were similar.
Besides directing the order of assembly, the standard BASIC linkers can also be modified to carry out other functions. To allow for idempotent assembly, linkers were also designed with additional methylated iP and iS sequences inserted to protect them from being recognised by BsaI. This methylation is lost following transformation and in vivo plasmid replication, and the plasmids can be extracted, purified, and used for further reactions. Because the linker sequence are relatively long (45bp for a standard linker), there is an opportunity to incorporate functional DNA sequences to reduce the number of DNA parts needed during assembly. The BASIC assembly standard provides several linkers embedded with RBS of different strengths. Similarly to facilitate the construction of fusion proteins containing multiple protein domains, several fusion linkers were also designed to allow for full read-through of the DNA construct. These fusion linkers code for a 15 amino acid glycine and serine polypeptide, which is an ideal linker peptide for fusion proteins with multiple domains.
During withdrawal of bromazepam or diazepam a fall in tryptophan, serotonin levels occurs as part of the benzodiazepine withdrawal syndrome. Changes in the levels of these chemicals in the brain can cause headaches, anxiety, tension, depression, insomnia, restlessness, confusion, irritability, sweating, dysphoria, dizziness, derealization, depersonalization, numbness/tingling of extremities, hypersensitivity to light, sound, and smell, perceptual distortions, nausea, vomiting, diarrhea, appetite loss, hallucinations, delirium, seizures, tremor, stomach cramps, myalgia, agitation, palpitations, tachycardia, panic attacks, short-term memory loss, and hyperthermia.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.